- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Payer-Related Barriers With Therapies Used for Uncomplicated UTIs
Panelists discuss how recurrent urinary tract infections (UTIs) treated with older antibiotics generate 2 to 3 times higher total costs than initial savings, warranting cost-effectiveness analyses in treatment decisions, whereas payers create barriers to newer therapies through restrictive authorizations, high co-pays, step therapy mandates, and limited formulary inclusion that providers can navigate via detailed documentation, pharmacy benefit manager engagement, patient assistance programs, and advocacy for evidence-based coverage policies.
EP: 1.Differentiating Uncomplicated and Complicated Urinary Tract Infections (UTIs)
EP: 2.Trends in Uncomplicated UTIs
EP: 3.Exploring Social Determinants of Health in Uncomplicated UTIs
EP: 4.Examining Uncomplicated UTI Recurrence
EP: 5.Role of Patients’ Education in Uncomplicated UTIs
EP: 6.Patient Burden Associated With Uncomplicated UTIs
EP: 7.Minimizing Antibiotic Resistance Development in Uncomplicated UTIs
EP: 8.Examining the Need for Updated Guidelines for Uncomplicated UTIs
EP: 9.Comparing Standard-of-Care Antibiotics for Uncomplicated UTIs
EP: 10.Patient Factors Influencing Antibiotic Selection in Uncomplicated UTIs
EP: 11.Recurrence Rates in Uncomplicated UTIs
EP: 12.Economic Burden Associated With Uncomplicated UTIs
EP: 13.Important Updates in the Management of Uncomplicated UTIs
EP: 14.Exploring Novel Options for the Management of Uncomplicated UTIs
EP: 15.Comparing Newer With Traditional Agents in Uncomplicated UTIs
EP: 16.Payer-Related Barriers With Therapies Used for Uncomplicated UTIs
EP: 17.Final Panel Thoughts on Uncomplicated UTI Management
Video content above is prompted by the following:
- To what extent does the economic burden of recurrence in patients treated with older, more affordable drugs offset the initial cost savings, and how should this affect treatment decisions?
- What payer-related barriers might arise for these emerging treatments for patients who have experienced treatment failure with traditional therapies?
- How can health care providers advocate for their patients in these situations?
Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO
May 2nd 2025To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.
Read More
Science at AACR Aims to Overcome Cancer Care Barriers
April 24th 2025A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.
Read More
